Table 3.
RBANS Total and Domain Scores
| Week | Rasagiline | Placebo | Mixed Model ANCOVA Estimates of Treatment Differences | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean (±SD) | N | Mean (±SD) | |||||||
| RBANS total scorea | 0 | 26 | 76.8 (12.5) | 23 | 74.2 (13.7) | |||||
| 12 | 26 | 78.7 (14.1) | 23 | 75.3 (14.5) | ||||||
| Change | 26 | 1.9 (6.9) | 23 | 1.1 (7.5) | ||||||
| RBANS Domainsb | Week | N | Mean (±SD) | N | Mean (±SD) | Diff. | SE | t | df | P value |
| Attention | 0 | 26 | 82.4 (15.2) | 23 | 76.8 (18.5) | |||||
| 12 | 26 | 84.0 (15.9) | 23 | 78.3 (17.2) | ||||||
| Change | 26 | 1.6 (10.6) | 23 | 1.6 (10.8) | 1.75 | 2.93 | −0.60 | 46.8 | 0.55 | |
| Delay memory | 0 | 26 | 77.6 (17.0) | 23 | 79.9 (18.7) | |||||
| 12 | 26 | 81.0 (17.5) | 23 | 79.2 (21.2) | ||||||
| Change | 26 | 3.4 (16.5) | 23 | −0.7 (13.0) | 3.40 | 4.07 | −0.83 | 47.0 | 0.41 | |
| Immediate memory | 0 | 26 | 79.8 (19.4) | 23 | 77.9 (19.4) | |||||
| 12 | 26 | 81.3 (20.6) | 23 | 78.5 (18.3) | ||||||
| Change | 26 | 1.4 (13.4) | 23 | 0.6 (11.6) | 1.40 | 3.48 | −0.40 | 46.1 | 0.69 | |
| Language | 0 | 26 | 88.2 (11.1) | 23 | 83.4 (8.4) | |||||
| 12 | 26 | 84.8 (14.3) | 23 | 85.7 (13.4) | ||||||
| Change | 26 | −3.4 (12.6) | 23 | 2.2 (15.4) | −4.18 | 3.79 | 1.10 | 47.1 | 0.28 | |
| Visuospatial | 0 | 26 | 81.6 (15.9) | 23 | 81.2 (19.0) | |||||
| 2 | 26 | 86.2 (16.0) | 23 | 80.5 (20.7) | ||||||
| Change | 26 | 4.6 (13.1) | 23 | −0.7 (13.8) | 5.44 | 3.67 | −1.48 | 46.8 | 0.14 | |
Note: RBANS, Repeatable Battery for the Assessment of Neuropsychological Status.
aRBANS total score was analyzed in a separate ANCOVA model (F = 0.63; df = 1,41.8; P = .43).
bRBANS domain scores were analyzed with the mixed model ANCOVA model: week 12 change = baseline score + domain + treatment + treatment × domain.